Antibody Content against Epstein-Barr Virus in Blood Extracellular Vesicles Correlates with Disease Activity and Brain Volume in Patients with Relapsing-Remitting Multiple Sclerosis

Int J Mol Sci. 2023 Sep 16;24(18):14192. doi: 10.3390/ijms241814192.

Abstract

We aimed to analyze whether EVs carry antibodies against EBV antigens and the possibility that they could serve as diagnostic and disease activity blood biomarkers in RRMS. This was a prospective and observational study including patients with RRMS with active and inactive disease and healthy controls. Blood EVs were isolated by precipitation. Titers of antibodies against nuclear (anti-EBNA1) and capsid (anti-VCA) EBV antigens in EVs and in plasma, as well as content of myelin antibodies in EVs were determined by ELISA. An exploratory analysis of correlations with clinical and radiological data was performed. Patients with RRMS had higher titers of anti-VCA inside EVs and free in plasma than healthy controls. Patients with active disease showed higher levels of anti-EBNA1 in EVs, but not in plasma, than patients with inactive disease. EV anti-VCA levels correlated with disease duration and with decreased brain volume structures-total brain, white matter, gray matter, cerebellum, hippocampus, -but not with T2/FLAIR lesion volume or EDSS, SDMT, or 9HPT. In addition, EV anti-VCA correlated with EV anti-MBP. The anti-VCA and anti-EBNA1 content in EVs could represent diagnostic and disease activity blood biomarkers, respectively, in RRMS.

Keywords: Epstein–Barr virus; antibodies; biomarker; extracellular vesicles; multiple sclerosis.

Grants and funding

This work was sponsored by a grant from Miguel Servet (CP20/00024 to Laura Otero-Ortega), predoctoral fellowships (FI18/00026 to Fernando Laso-García, FI22/00009 to Maria Paz López), Río-Hortega grant (CM22/00065 to Gabriel Torres Iglesias), and investigation project (PI21/00918) from the Carlos III Institute for health research and cofunded by the European Union.